-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits VEGF binding to its receptors by specifically targeting human vascular endothelial growth factor (VEGF), inhibits the formation of tumor blood vessels, reduces the supply of blood, oxygen and other nutrients to tumors, thereby inhibiting tumor cell growth
.
Bevacizumab was approved by the U.
S.
Food and Drug Administration in 2004 and entered the Chinese market
in 2010.
As one of the important drugs for anti-tumor angiogenesis, bevacizumab has been used in the treatment
of a variety of malignant tumors.
1.
Applicable diseases